31 July

Several pharmaceutical companies are racing to develop a vaccine for the Covid-19 virus that has wreaked havoc on the world economy.

While one shot of the vaccine was initially thought to provide immunity against the virus, reports are now emerging that two or more annual vaccinations may be required.

Daniel Lacalle, an economist and author, shared an article on AstraZeneca CEO’s concerns that the unpredictable nature of the Covid-19 virus may require annual vaccinations.

AstraZeneca is currently working on a vaccine in partnership with the Oxford University, which has produced a positive immune response in early stage human clinical trials.

Based on the technology used for developing a vaccine for SARS 1, the immunity provided by the vaccine may last for only 12 to 18 months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The exact required vaccination period is not known due to the unpredictable nature of the virus.

In other news, Ludovic Subran, chief economist at Allianz, shared an article on a surge in insolvencies in the second quarter of 2020 across the world.

Approximately 147 companies with a turnover of more than €50m ($56.2m) went insolvent during the quarter.

Read more